Teachers Retirement System of The State of Kentucky Increases Stock Holdings in Bristol Myers Squibb Company $BMY

Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 76.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 484,912 shares of the biopharmaceutical company’s stock after purchasing an additional 209,700 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Bristol Myers Squibb were worth $21,869,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the second quarter worth approximately $1,554,154,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after purchasing an additional 10,195,775 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Bristol Myers Squibb by 428.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after acquiring an additional 9,171,098 shares during the period. Man Group plc increased its holdings in Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after purchasing an additional 5,503,391 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of Bristol Myers Squibb by 142.8% during the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock valued at $390,541,000 after acquiring an additional 4,961,869 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have commented on BMY. Piper Sandler restated an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a research note on Friday, February 6th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $60.71.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $61.28 on Wednesday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The company has a market cap of $124.79 billion, a P/E ratio of 17.76, a P/E/G ratio of 0.18 and a beta of 0.26. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The firm’s fifty day moving average is $57.27 and its two-hundred day moving average is $50.76.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the previous year, the business earned $1.67 earnings per share. The business’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.